Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.86
RP's Cash-to-Debt is ranked lower than
75% of the 1921 Companies
in the Global Software - Application industry.

( Industry Median: 10.13 vs. RP: 0.86 )
Ranked among companies with meaningful Cash-to-Debt only.
RP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 1.02 Max: No Debt
Current: 0.86
Equity-to-Asset 0.49
RP's Equity-to-Asset is ranked lower than
66% of the 1830 Companies
in the Global Software - Application industry.

( Industry Median: 0.60 vs. RP: 0.49 )
Ranked among companies with meaningful Equity-to-Asset only.
RP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.97  Med: 0.52 Max: 0.63
Current: 0.49
-0.97
0.63
Interest Coverage 8.31
RP's Interest Coverage is ranked lower than
81% of the 1467 Companies
in the Global Software - Application industry.

( Industry Median: 173.79 vs. RP: 8.31 )
Ranked among companies with meaningful Interest Coverage only.
RP' s Interest Coverage Range Over the Past 10 Years
Min: 0.56  Med: 3.57 Max: 20.02
Current: 8.31
0.56
20.02
Piotroski F-Score: 6
Altman Z-Score: 4.91
Beneish M-Score: -3.03
WACC vs ROIC
9.12%
4.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 5.50
RP's Operating Margin % is ranked higher than
52% of the 1862 Companies
in the Global Software - Application industry.

( Industry Median: 4.84 vs. RP: 5.50 )
Ranked among companies with meaningful Operating Margin % only.
RP' s Operating Margin % Range Over the Past 10 Years
Min: -3.83  Med: 3.34 Max: 5.72
Current: 5.5
-3.83
5.72
Net Margin % 2.93
RP's Net Margin % is ranked lower than
51% of the 1863 Companies
in the Global Software - Application industry.

( Industry Median: 3.19 vs. RP: 2.93 )
Ranked among companies with meaningful Net Margin % only.
RP' s Net Margin % Range Over the Past 10 Years
Min: -2.85  Med: 0.04 Max: 20.18
Current: 2.93
-2.85
20.18
ROE % 4.83
RP's ROE % is ranked lower than
54% of the 1803 Companies
in the Global Software - Application industry.

( Industry Median: 6.16 vs. RP: 4.83 )
Ranked among companies with meaningful ROE % only.
RP' s ROE % Range Over the Past 10 Years
Min: -5.42  Med: -0.62 Max: 7.27
Current: 4.83
-5.42
7.27
ROA % 2.30
RP's ROA % is ranked lower than
53% of the 1927 Companies
in the Global Software - Application industry.

( Industry Median: 2.92 vs. RP: 2.30 )
Ranked among companies with meaningful ROA % only.
RP' s ROA % Range Over the Past 10 Years
Min: -3.14  Med: 0.03 Max: 23.26
Current: 2.3
-3.14
23.26
ROC (Joel Greenblatt) % 28.73
RP's ROC (Joel Greenblatt) % is ranked higher than
54% of the 1883 Companies
in the Global Software - Application industry.

( Industry Median: 23.13 vs. RP: 28.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35.98  Med: 27.78 Max: 49.41
Current: 28.73
-35.98
49.41
3-Year Revenue Growth Rate 13.80
RP's 3-Year Revenue Growth Rate is ranked higher than
74% of the 1454 Companies
in the Global Software - Application industry.

( Industry Median: 5.30 vs. RP: 13.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.6 Max: 13.8
Current: 13.8
0
13.8
3-Year EBITDA Growth Rate 16.50
RP's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 1210 Companies
in the Global Software - Application industry.

( Industry Median: 8.40 vs. RP: 16.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.25 Max: 16.5
Current: 16.5
0
16.5
3-Year EPS without NRI Growth Rate -8.00
RP's 3-Year EPS without NRI Growth Rate is ranked lower than
69% of the 1098 Companies
in the Global Software - Application industry.

( Industry Median: 7.70 vs. RP: -8.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -26.5 Max: 86.6
Current: -8
0
86.6
GuruFocus has detected 3 Warning Signs with RealPage Inc $RP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RP's 10-Y Financials

Financials (Next Earnings Date: 2017-05-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RP Guru Trades in Q1 2016

Joel Greenblatt 10,222 sh (New)
Paul Tudor Jones 34,841 sh (+155.06%)
Jim Simons 600,100 sh (+42.61%)
Murray Stahl 24,929 sh (-3.12%)
RS Investment Management 782,107 sh (-54.83%)
» More
Q2 2016

RP Guru Trades in Q2 2016

Jim Simons 708,700 sh (+18.10%)
Paul Tudor Jones 38,359 sh (+10.10%)
Joel Greenblatt Sold Out
RS Investment Management 781,881 sh (-0.03%)
Murray Stahl 19,148 sh (-23.19%)
» More
Q3 2016

RP Guru Trades in Q3 2016

Steven Cohen 85,100 sh (New)
Jim Simons 681,600 sh (-3.82%)
Murray Stahl 15,954 sh (-16.68%)
Paul Tudor Jones 31,023 sh (-19.12%)
» More
Q4 2016

RP Guru Trades in Q4 2016

Jim Simons 621,600 sh (-8.80%)
Murray Stahl 13,853 sh (-13.17%)
Paul Tudor Jones 25,048 sh (-19.26%)
Steven Cohen 28,600 sh (-66.39%)
» More
» Details

Insider Trades

Latest Guru Trades with RP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Software - Application    NAICS: 511210    SIC: 7372
Compare:NYSE:MULE, NYSE:ZEN, NAS:PFPT, NAS:VRNT, NAS:PEGA, NYSE:ELLI, NYSE:PAYC, NYSE:TWLO, NAS:ACIW, NAS:NTCT, NAS:MANH, NAS:BLKB, NYSE:DBD, NAS:MDRX, NAS:CVLT, NAS:TIVO, NAS:FEYE, NAS:CSOD, NYSE:HUBS, NAS:MSTR » details
Traded in other countries:1R1.Germany,
Headquarter Location:USA
RealPage Inc provides on demand software and software-enabled services for the rental housing and vacation rental industries. It provides property management solutions to customers for managing their marketing, pricing, leasing operations, among others.

RealPage Inc. is a provider of on-demand software and software-enabled solutions for the rental housing industry. Its customers include single family, multifamily, and vacation rental units, and large property management companies. Its solutions include marketing, pricing, leasing, accounting, purchasing, and other property operation capabilities. The RealPage platform hosts applications that enable property owners and managers to improve pricing methodologies, improve collections, and integrate business processes. The company derives revenue from on-demand and on-premises software solutions and professional services. All of the firm's revenue is generated in the United States.

Top Ranked Articles about RealPage Inc

RepliCel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Apr 29, 2016) - RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCF)(TSX VENTURE:RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today approval by the TSX Venture Exchange (the "TSXV") to extend the term of 3,765,834 share purchase warrants (the "Extended Warrants"). The Company approved the closing of a private placement on May 9, 2014 (the "May PP") pursuant to which it issued 3,717,167 units and a private placement on June 16, 2014 (the "June PP" and, collectively with the May PP, the "Private Placement") pursuant to which it issued 866,000 units. Of the 4,583,167 warrants issued in connection with the Private Placement (the "Warrants"), the original term of the 3,717,167 Warrants issued in the May PP was two years and expired on May 9, 2016 and the original term of the 866,000 Warrants issued in the June PP was two years and expired on June 16, 2016. Holders of 30,000 Warrants of the May PP exercised their Warrants on February 19, 2016, holders of 487,333 Warrants of the May PP exercised their Warrants on February 24, 2016 and holders of 200,000 Warrants of the June PP exercised their Warrants on February 22, 2016. The Company has now extended the expiry date of the Warrants for a further two year period to May 9, 2018 for 3,099,834 of the Warrants and to June 16, 2018 for 666,000 of the Warrants. In all other respects the terms of the Warrants remain unchanged and in full force and effect. The Company also announced approval by the TSXV to amend the exercise price of unexercised portion of the 3,765,834 Warrants (the "Repriced Warrants") from $1.00 to $0.50 for the first year and from $1.25 to $0.50 for the second year. In accordance with the policies of the TSXV, the exercise period for the Repriced Warrants will also be amended by reducing the exercise period to 30 days if, for any ten consecutive trading days during the unexpired term of the Repriced Warrants, the closing price of the Company's listed shares exceeds $0.625. In all other respects the terms of the Repriced Warrants remain unchanged and in full force and effect. About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Company's product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCel's innovative technology utilizing cell populations isolated from a patient's healthy hair follicles. The Company has also developed a propriety injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications. Please visit www.replicel.com for additional information. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





CORPORATE/INVESTOR RELATIONS:
RepliCel Life Sciences Inc.
Lee Buckler
CEO and President
604-248-8693
[email protected]
MEDIA:
RepliCel Life Sciences Inc.
Jacqui Specogna
604-248-8730
[email protected]
www.replicel.com




Read more...
RepliCel Life Sciences Conducts Formal Consultation Review With Japan's PMDA and Receives Unprecedented Review Fee Reduction

Japan's Pharmaceuticals and Medical Devices Agency reviews RepliCel's pre-clinical, quality, and manufacturing data for its non-bulbar dermal sheath (NBDS) platform

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Apr 25, 2016) - RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSX VENTURE:RP)(FRANKFURT:P6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced that it met this month with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in Tokyo. The meeting was a formal consultation review of the company's pre-clinical, quality, and manufacturing data related to its non-bulbar dermal sheath (NBDS) platform technology. This review is a required step in the process to obtain PMDA consent to perform a clinical trial in Japan. "We have been very encouraged by the PMDA's collaborative approach and yet the absolute high standards of safety they maintain," stated R. Lee Buckler, President & CEO, RepliCel Life Sciences Inc. "The conduct of this consultation meeting moves the clinical-stage products (RCT-01 tendon repair; RCS-01 skin rejuvenation) being developed from our NBDS platform closer to the launch of Japanese clinical trials and partnerships," he added. Furthermore, each consultation performed by the PMDA at the formal request of a potential clinical trial sponsor, carries with it associated fees which are lowered for academic institutions, hospitals, and small/medium enterprises. Additionally all documentation created for the consultation must be provided in Japanese. Without any known precedent for doing so, RepliCel, on the advice of CJ Partners Inc., applied for the reduced-fee designation based on its small size and the pre-revenue nature of its business. The company was successfully awarded a reduced fee status which represents approximately one-tenth of the otherwise applicable fees. "To the extent that CJ Partners knows, this is the first time that a foreign regenerative medicine company has qualified for the reduced price status with the PMDA," commented Colin Lee Novick, Managing Director of CJ Partners Inc. "RepliCel continues to pioneer foreign participation in cell therapy development in Japan," said Buckler. "We are committed to early commercialization of our products in Japan and entering into a Japanese-based partnership for each product in our cell therapy portfolio." About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Company's product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles. The Company has also developed a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications. Please visit www.replicel.com for additional information. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements Certain statements in this press release related to the Program are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the number of Warrant Holders that may participate in the Program, the use of proceeds and final regulatory approval. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.





CORPORATE:
RepliCel Life Sciences Inc.
Lee Buckler
CEO and President
604-248-8693
[email protected]
MEDIA/INVESTOR RELATIONS:
RepliCel Life Sciences Inc.
Jacqui Specogna
604-248-8730
[email protected]
www.replicel.com




Read more...

Ratios

vs
industry
vs
history
PE Ratio 175.47
RP's PE Ratio is ranked lower than
93% of the 1245 Companies
in the Global Software - Application industry.

( Industry Median: 25.80 vs. RP: 175.47 )
Ranked among companies with meaningful PE Ratio only.
RP' s PE Ratio Range Over the Past 10 Years
Min: 41.13  Med: 148.24 Max: 2580
Current: 175.47
41.13
2580
Forward PE Ratio 40.32
RP's Forward PE Ratio is ranked lower than
83% of the 535 Companies
in the Global Software - Application industry.

( Industry Median: 20.20 vs. RP: 40.32 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 175.47
RP's PE Ratio without NRI is ranked lower than
93% of the 1229 Companies
in the Global Software - Application industry.

( Industry Median: 26.21 vs. RP: 175.47 )
Ranked among companies with meaningful PE Ratio without NRI only.
RP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 41.13  Med: 148.24 Max: 2580
Current: 175.47
41.13
2580
Price-to-Owner-Earnings 42.51
RP's Price-to-Owner-Earnings is ranked lower than
75% of the 724 Companies
in the Global Software - Application industry.

( Industry Median: 22.94 vs. RP: 42.51 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
RP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 30.25  Med: 81.68 Max: 311.86
Current: 42.51
30.25
311.86
PB Ratio 7.78
RP's PB Ratio is ranked lower than
79% of the 1789 Companies
in the Global Software - Application industry.

( Industry Median: 2.97 vs. RP: 7.78 )
Ranked among companies with meaningful PB Ratio only.
RP' s PB Ratio Range Over the Past 10 Years
Min: 3.77  Med: 5.85 Max: 27.28
Current: 7.78
3.77
27.28
PS Ratio 5.02
RP's PS Ratio is ranked lower than
71% of the 1780 Companies
in the Global Software - Application industry.

( Industry Median: 2.34 vs. RP: 5.02 )
Ranked among companies with meaningful PS Ratio only.
RP' s PS Ratio Range Over the Past 10 Years
Min: 2.7  Med: 4.28 Max: 7.67
Current: 5.02
2.7
7.67
Price-to-Free-Cash-Flow 46.89
RP's Price-to-Free-Cash-Flow is ranked lower than
75% of the 677 Companies
in the Global Software - Application industry.

( Industry Median: 24.32 vs. RP: 46.89 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 20.2  Med: 43.02 Max: 85.75
Current: 46.89
20.2
85.75
Price-to-Operating-Cash-Flow 20.99
RP's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 856 Companies
in the Global Software - Application industry.

( Industry Median: 17.68 vs. RP: 20.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.16  Med: 22.69 Max: 48.85
Current: 20.99
13.16
48.85
EV-to-EBIT 90.75
RP's EV-to-EBIT is ranked lower than
90% of the 1770 Companies
in the Global Software - Application industry.

( Industry Median: 17.68 vs. RP: 90.75 )
Ranked among companies with meaningful EV-to-EBIT only.
RP' s EV-to-EBIT Range Over the Past 10 Years
Min: -640.7  Med: 89.5 Max: 2705
Current: 90.75
-640.7
2705
EV-to-EBITDA 32.96
RP's EV-to-EBITDA is ranked lower than
81% of the 1910 Companies
in the Global Software - Application industry.

( Industry Median: 13.76 vs. RP: 32.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
RP' s EV-to-EBITDA Range Over the Past 10 Years
Min: 23.4  Med: 39.2 Max: 73.5
Current: 32.96
23.4
73.5
PEG Ratio 20.47
RP's PEG Ratio is ranked lower than
93% of the 567 Companies
in the Global Software - Application industry.

( Industry Median: 1.98 vs. RP: 20.47 )
Ranked among companies with meaningful PEG Ratio only.
RP' s PEG Ratio Range Over the Past 10 Years
Min: 20.47  Med: 33.9 Max: 187.13
Current: 20.47
20.47
187.13
Current Ratio 1.19
RP's Current Ratio is ranked lower than
76% of the 1750 Companies
in the Global Software - Application industry.

( Industry Median: 1.94 vs. RP: 1.19 )
Ranked among companies with meaningful Current Ratio only.
RP' s Current Ratio Range Over the Past 10 Years
Min: 0.65  Med: 1.03 Max: 1.81
Current: 1.19
0.65
1.81
Quick Ratio 1.18
RP's Quick Ratio is ranked lower than
73% of the 1750 Companies
in the Global Software - Application industry.

( Industry Median: 1.79 vs. RP: 1.18 )
Ranked among companies with meaningful Quick Ratio only.
RP' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 1.03 Max: 1.81
Current: 1.18
0.65
1.81
Days Inventory 3.02
RP's Days Inventory is ranked higher than
80% of the 1086 Companies
in the Global Software - Application industry.

( Industry Median: 18.20 vs. RP: 3.02 )
Ranked among companies with meaningful Days Inventory only.
RP' s Days Inventory Range Over the Past 10 Years
Min: 0.5  Med: 1.25 Max: 3.02
Current: 3.02
0.5
3.02
Days Sales Outstanding 59.34
RP's Days Sales Outstanding is ranked higher than
60% of the 1492 Companies
in the Global Software - Application industry.

( Industry Median: 68.98 vs. RP: 59.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
RP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.34  Med: 59.34 Max: 89.04
Current: 59.34
57.34
89.04
Days Payable 32.27
RP's Days Payable is ranked lower than
62% of the 1330 Companies
in the Global Software - Application industry.

( Industry Median: 43.37 vs. RP: 32.27 )
Ranked among companies with meaningful Days Payable only.
RP' s Days Payable Range Over the Past 10 Years
Min: 22.1  Med: 29.48 Max: 41.23
Current: 32.27
22.1
41.23

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
RP's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 1148 Companies
in the Global Software - Application industry.

( Industry Median: -2.60 vs. RP: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43.8  Med: -2.05 Max: 0
Current: -1.1
-43.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 59.44
RP's Price-to-Tangible-Book is ranked lower than
97% of the 1488 Companies
in the Global Software - Application industry.

( Industry Median: 4.38 vs. RP: 59.44 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 34.43  Med: 48.78 Max: 99.86
Current: 59.44
34.43
99.86
Price-to-Intrinsic-Value-Projected-FCF 3.34
RP's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
69% of the 771 Companies
in the Global Software - Application industry.

( Industry Median: 1.97 vs. RP: 3.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.72  Med: 2.87 Max: 3.36
Current: 3.34
2.72
3.36
Price-to-Median-PS-Value 1.18
RP's Price-to-Median-PS-Value is ranked higher than
52% of the 1498 Companies
in the Global Software - Application industry.

( Industry Median: 1.15 vs. RP: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.86  Med: 1.1 Max: 1.58
Current: 1.18
0.86
1.58
Price-to-Graham-Number 21.68
RP's Price-to-Graham-Number is ranked lower than
98% of the 882 Companies
in the Global Software - Application industry.

( Industry Median: 2.52 vs. RP: 21.68 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RP' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 11.52  Med: 17.65 Max: 37.19
Current: 21.68
11.52
37.19
Earnings Yield (Greenblatt) % 1.10
RP's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 2521 Companies
in the Global Software - Application industry.

( Industry Median: 3.23 vs. RP: 1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 0.6 Max: 1.8
Current: 1.1
0.1
1.8
Forward Rate of Return (Yacktman) % 6.30
RP's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 773 Companies
in the Global Software - Application industry.

( Industry Median: 10.33 vs. RP: 6.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RP' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.3  Med: -3.8 Max: 9
Current: 6.3
-9.3
9

More Statistics

Revenue (TTM) (Mil) $568.1
EPS (TTM) $ 0.21
Beta1.18
Short Percentage of Float1.69%
52-Week Range $20.01 - 37.65
Shares Outstanding (Mil)80.96

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 674 759 885
EPS ($) 0.91 1.10 1.34
EPS without NRI ($) 0.91 1.10 1.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RP

Headlines

Articles On GuruFocus.com
RepliCel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price Apr 29 2016 
RepliCel Life Sciences Conducts Formal Consultation Review With Japan's PMDA and Receives Unpreceden Apr 25 2016 
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trial Apr 20 2016 
RepliCel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates Apr 08 2016 
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement Apr 06 2016 
RepliCel Announces CEO Update Feb 16 2016 
Weekly CEO Sales Highlight: Realpage, Anadigics, Emergent BioSolutions, ScanSource Jan 03 2016 
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV- Dec 17 2015 
RepliCel Life Sciences Announces Leadership Transition Dec 16 2015 
RepliCel Life Sciences to Present at World Stem Cell Summit 2014 Dec 02 2014 

More From Other Websites
RealPage® Portfolio Asset Management Tool Selected by Real Estate Investment Management Firm, PCCP,... Apr 12 2017
RealPage® Launches Industry’s First Software Solution Tailored to the Needs of Mid-Market... Apr 04 2017
As occupancy falls again, apartment landlords sweeten the pot Mar 31 2017
America is building more apartments than renters want Mar 30 2017
RealPage® and Axiometrics® Report Dropping Apartment Occupancy, but Rents Continue to Grow Mar 30 2017
Post Earnings Coverage as Alarm.com's Q4 Top-line Surged 23%; Outshined Forecasts Mar 28 2017
Real Estate Advisory Firm RCLCO Selects RealPage® Portfolio Asset Management Software Mar 27 2017
Report: Houston riskiest market nationally for multifamily investors Mar 20 2017
RealPage, Inc. :RP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
Edited Transcript of RP earnings conference call or presentation 27-Feb-17 10:00pm GMT Feb 28 2017
RealPage makes $300M acquisition of revenue management system Feb 27 2017
RealPage posts 4Q profit Feb 27 2017
RealPage® to Acquire Lease Rent Options, LRO® Feb 27 2017
RealPage Reports Fourth Quarter and Full Year 2016 Financial Results Feb 27 2017
RealPage to Participate in Two Upcoming Investor Conferences Feb 27 2017
Technology Stocks' Q4 Earnings on Feb 27: WDAY, RP & SSTK Feb 24 2017
Morgan Properties Extends Relationship with RealPage Contact Center Feb 22 2017
RealPage to Announce Fourth Quarter and Full Year 2016 Financial Results Feb 20 2017
RealPage Names Brock MacLean to SVP of Business Development Feb 13 2017
RealPage Portfolio Asset Management Tool Chosen by Global Investment Firm Harbert Management Corp. Feb 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)